Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Baird Maintains Neutral on Maravai LifeSciences, Lowers Price Target to $2

Author: Benzinga Newsdesk | May 13, 2025 07:30am
Baird analyst Catherine Schulte maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and lowers the price target from $3 to $2.

Posted In: MRVI

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist